Letter to the Editor

A regional Canadian expert consensus on recommendations for restoring exercise and pulmonary function testing in low and moderate-to-high community prevalence coronavirus disease 2019 (COVID-19) settings

Sarah Khan MD1, Kara K. Tsang BHSc2, Dominik Mertz MD3, Myrna Dolovich BEng, PEng3, Marcel Tunks MD4, Catherine Demers MD5, Kelly Hassall RRT, FCSRT, MEd5, Neil Maharaj MD7, Karen Margallo8, Maureen Cividino MD9, Zain Chagla MD10 and MyLinh Duong MBBS11

1Infection Prevention and Control, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada, 2Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada, 3Faculty of Health Sciences, Aerosol Research, McMaster University, Hamilton, Ontario, Canada, 4Division of Respiratory, St Joseph’s Hospital, McMaster University, Hamilton, Ontario, Canada, 5Division of Cardiology and Health Evidence and Impact, McMaster University, Hamilton, Ontario, Canada, 6Respiratory Therapy Department St Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada, 7Michael G DeGroote School of Medicine and Niagara Peninsula Medicine & Diagnostics, McMaster University, Hamilton, Ontario, Canada, 8Medical Diagnostic Unit, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada, 9Occupational Health, St Joseph’s Hospital, McMaster University, Hamilton, Ontario, Canada, 10Infection Prevention and Control, St Joseph’s Hospital, McMaster University, Hamilton, Ontario, Canada and 11Division of Respirology, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada

To the Editor—Exercise and pulmonary function testing (PFT) are critical for the diagnosis, monitoring and management of cardiopulmonary disease. Previous respiratory pandemics have not impacted healthcare services to the same extent as coronavirus disease 2019 (COVID-19). Infection-specific guidance is now urgently needed to facilitate the resumption of pulmonary diagnostic services for low and moderate-to-high prevalence COVID-19 settings. Central to guidance development is the assessment of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) transmission risk associated with these procedures, which are not recognized as aerosol-generating medical procedures (AGPs). However, they may carry risk due to the likelihood of generating coughs, exhaled respiratory droplets, and aerosols from the high ventilation and forced expiratory efforts. To date, there is no direct evidence for the risk of SARS-CoV-2 transmission in this context; thus, all guidelines are based on expert opinion from respiratory expert bodies.1–6 The aim of this document is to provide guidance for restoring exercise and pulmonary function testing in low and moderate-to-high prevalence settings of the COVID-19 pandemic. These recommendations are based on consensus from cardiopulmonary diagnostic service, occupational health, respiratory therapy, aerosol research, infection prevention and control (IPAC), and public health stakeholders to facilitate a uniform approach to the uptake and implementation of these recommendations. As further evidence emerges, revisions of these recommendations may be needed.

Methods

We undertook a literature review of guidelines and studies published in English between January 1, 2012, and September 30, 2020, on aerosol and droplet generation including risks for viral transmission during exercise testing and PFT. We communicated with respiratory community members across Canada to ascertain the scope of and variation in conducting these procedures during the pandemic. We met with regional experts and stakeholders to discuss the available evidence on prescreening, aerosol and droplet generation, transmission risk, personal protective equipment (PPE) appropriateness, and infection control measures relevant to SARS-CoV-2. We developed recommendations for the restoration of exercise testing and PFT in low and moderate-to-high prevalence COVID-19 settings, defined by the rate of community transmission (excluding institutional outbreaks) below and exceeding 20 per 100,000 cases per week, respectively.

Results

Through direct communication with pulmonary diagnostic laboratories across Canada, we found wide variation in the delivery of these services during the pandemic and in the post-peak phase. We noted variable practices in screening procedures, COVID-19 testing, and PPE (procedural/surgical masks vs N95 respirators) across laboratories within and between institutions. We searched for international, national,1–5 and provincial6 guidelines that provided recommendations for low or moderate-to-high community prevalence settings. Only 1 guideline provided recommendations for both settings. All were opinions from respiratory expert bodies and regarded these procedures as high risk for airborne infection transmission. As such, enhanced PPE and airborne precautions were recommended. No direct data were available regarding the risk of SARS-CoV-2 transmission related to pulmonary diagnostic procedures. Table 1 highlights

Author for correspondence: Sarah Khan, E-mail: khan259@mcmaster.ca

Cite this article: Khan S, et al. (2020). A regional Canadian expert consensus on recommendations for restoring exercise and pulmonary function testing in low and moderate-to-high community prevalence coronavirus disease 2019 (COVID-19) settings. Infection Control & Hospital Epidemiology, https://doi.org/10.1017/ice.2020.1339

© The Author(s), 2020. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Table 1. Recommendations for Low and Moderate-to-High COVID-19 Prevalence Settings**

| Prescreening Questionnaire* | Recommendations |
|-----------------------------|------------------|
| Prescreening questionnaire should be implemented at the time of informing patient of appointment, preferably 24–48 h prior to the test. Screening questionnaires will assess for any CHANGES or NEW symptoms as a potential indicator of active infection, or known COVID-19 exposures and as such will require COVID-19 testing. |
| 1. Is the patient coming from an institution currently in outbreak or does the patient have a pending COVID-19 test because the patient is or was symptomatic? YES NO |
| 2. Did you/the patient have close contact with anyone with acute respiratory illness or travelled outside Ontario in the last 14 days? YES NO |
| 3. Have you/the patient have a confirmed case of COVID-19 or had close contact with a confirmed case of Covid-19? YES NO |
| 4. Do you/the patient have any of the following symptoms: |
| Fever |
| Sore throat |
| Headache |
| Chills |
| Unexplained fatigue, malaise, muscle aches (myalgias) |
| New onset cough |
| Worsening chronic cough |
| Shortness of breath |
| Difficulty breathing |
| Difficulty swallowing |
| Decrease or loss of sense of taste or smell |
| Pink eye (conjunctivitis) |
| Runny nose/nasal congestion without other known cause |
| Red/purple lesions on hands/feet |
| NO |
| YES—if yes, please circle the symptom(s) |
| 5. If the patient is 70 years of age or older, are they experiencing any of the following symptoms: delirium, unexplained or increased number of falls, acute functional decline, or worsening chronic conditions? |
| NO |
| YES |

| Patient risk stratification | High COVID-19 risk | Low COVID-19 risk | Negligible COVID-19 risk |
|-----------------------------|--------------------|-------------------|-------------------------|
| NPS result OR symptoms OR exposure history | NPS positive | NPS pending | NPS negative and no exposures |
| One of the following: |
| • Symptoms not explained by other diagnosis |
| • Unable to get a history |
| COVID-19 exposed and any symptoms |
| One of the following: |
| • Symptoms explained by another diagnosis |
| COVID-19 exposed and NO symptoms |
| One of the following: |
| No exposures AND no symptoms (no NPS unless AGMP planned during moderate-to-high prevalence) |
| Resolved case of COVID-19 >14 d but <3 months ago (immune) |

| Action | Postpone for minimum 14 d AND improved symptoms for 72 h | Postpone testing until NPS result available | Proceed with testing |
|---------|-------------------------------------------------------------|---------------------------------------------|----------------------|

| Testing modality | Exercise stress testing | Cardiopulmonary exercise testing | PFT spirometry |
|------------------|-------------------------|---------------------------------|----------------|

| Personal protective equipment (PPE) | Low prevalence | Mod-to-high prevalence |
|-------------------------------------|----------------|------------------------|
| Droplets and contact precautions: surgical/procedural masks and face shield. Frequent hand washing, avoid touching of face/mucus membranes. Isolation gowns and gloves based on point of care risk assessment. |

| Other considerations | |
|----------------------| |
| • Plexiglass barriers or screen as a physical barrier may be considered where feasible |
| • Cleaning instructions of flow sensors as per manufacturer’s instructions |
| • High bacteria and pathogen filters for PFT spirometry equipment |
| • Ensure room air exchange is 6–12 cycles/h<sup>10</sup> |
| • Modifications to procedural scheduling to accommodate for time needed for cleaning, ventilation, donning/doffing between PPE |

| Cleaning procedures | Wiping of all surfaces with hospital grade disinfectants between patients within a 2-m radius of patients, or within 3 m if patients are in an elevated position, such as a treadmill. Settling time not required. |

Note. PFT, pulmonary function testing; NPS, nasopharyngeal swabs for PCR detection of SARS-CoV-2.
the recommendations that were developed through consensus with stakeholders and after consideration of the limited available evidence.

Discussion

As cases of COVID-19 fluctuate, it is important to provide infection-specific guidance to facilitate the care of patients with cardiopulmonary disease. In our literature search, we found robust evidence supporting the generation of respiratory aerosols and droplets of varying sizes with coughing, sneezing, speech, singing, and breathing. There were no large or robust studies for the level of aerosols and respiratory droplets generated with spirometry or exercise testing. However, it is reasonable to assume that the deep exhalation and coughing associated with these pulmonary diagnostic procedures leads to aerosol and respiratory droplet generation. All previous guidelines have cautioned against these procedures as high-risk for airborne transmission and have recommended N95 respirators for protection. This recommendation is further supported by detectable SARS-CoV-2 viral RNA and viable virus within aerosol-droplet surrounding areas distant from infected patients, suggesting the potential for airborne transmission. However, no data to date have indicated that droplets carry sufficient viable virus to result in infection transmission; thus, it is not relevant in the healthcare setting. Furthermore, no strong data support meaningful reduction in transmission risk with use of N95 respirator instead of surgical masks for non-AGPs. For these reasons, we recommend the use of droplet and contact precautions with surgical or procedural masks and eye protection for these diagnostic procedures. If the point-of-care risk assessment suggests potentially elevated exposure risk, then isolation gowns and gloves may be added in a low-prevalence setting. In settings with low and moderate-to-high prevalence, pulmonary function testing should be deferred in patients who are risk-stratified as high risk for COVID-19.

Similar to other guidelines, we recommend that all facilities ensure that current recommended standards for heating, ventilation, and air conditioning are met, including temperature, humidity, and air changes. Environmental conditions likely play a role in cases in which aerosol transmission is the predominant mode of COVID-19 infection. Furthermore, under laboratory conditions, these environmental factors have been shown to determine the travel trajectory of expired particles. Lastly, universal masking and physical distancing should be maintained.

In conclusion, we developed COVID-19–specific recommendations for restoring exercise and PFT using a process of consensus involving all relevant key stakeholders because there are no data available to inform the risk of SARS-CoV-2 transmission related to these pulmonary diagnostic procedures. Our guidance document incorporates a patient- and community-level risk-stratified approach that will facilitate the uniform adoption of IPAC practices across laboratories while protecting patients and staff in low- and high-prevalence settings.

Acknowledgments.

Financial support. No financial support was provided relevant to this article.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

1. Stanojevic S, Beaucage F, Comondore V, et al. Resumption of pulmonary function testing during the post-peak phase of the COVID-19 pandemic: a position statement from the Canadian Thoracic Society and the Canadian Society of Respiratory Therapists. Canadian Thoracic Society website. https://cts-sct.ca/wp-content/uploads/2020/07/CTS_CSRT_COVID_PFT_Final-July12_2020.pdf. Published 2020. Accessed November 20, 2020.
2. Wilson KC, Kaminsky DA, Michaud G, et al. Restoring pulmonary and sleep services as the COVID-19 pandemic lessens: from an association of pulmonary, critical care, and sleep division directors and American Thoracic Society–coordinated task force. Ann Am Thorac Soc 2020;17:1343–1351.
3. Singh SJ, Bolton C, Nolan C, et al. BTS Guidance for pulmonary rehabilitation—opening services for the ‘business as usual’ participants. British Thoracic Society website. https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/pulmonary-rehabilitation-reopening-services-for-the-business-as-usual-participants/. Published 2020. Accessed November 20, 2020.
4. European Respiratory Society. Recommendation from ERS Group 9.1 (Respiratory function technologists /Scientists) lung function testing during COVID-19 pandemic and beyond. Black Lung Center of Excellence website. https://blacklungcoe.org/european-respiratory-society-ers-recommendations-on-lung-function-testing-during-the-covid-19-pandemic-and-beyond/. Published 2020. Accessed November 20, 2020.
5. Position statement on procedures creating a heightened risk of infection during an outbreak of a communicable respiratory disease. The Canadian Society of Respiratory Therapists website. https://www.csrt.com/wp-content/uploads/CSRT-Procedures-Duringan-Outbreak-April-2020-v2.pdf. Published 2020. Accessed November 20, 2020.
6. Ontario Agency for Health Protection and Promotion (Public Health Ontario). IPAC Recommendations for Use of Personal Protective Equipment for Care of Individuals With Suspected or Confirmed COVID-19. Toronto: Queen’s Printer for Ontario; 2020.
7. Anfinrud P, Stadnynskyi V, Bax CE, Bax A. Visualizing speech-generated oral fluid droplets with laser light scattering. N Engl J Med 2020;382:2061–2063.
8. Liu Y, Nong Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature 2020;582:557–560.
9. Lu J, Gu J, Li K, et al. COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020. Emerg Infect Dis 2020;26:1628–1631.
10. Guidelines for environmental infection control in health-care facilities. Appendix B. Air. Centers for Disease Control and Prevention website. https://www.cdc.gov/infectioncontrol/guidelines/environmental/appendix/air.html. Published 2003. Accessed September 28, 2020.